Download Date of Document: March 24, 2017 CURRICULUM VITAE

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
70. Yu XM, Jaskula-Sztul R, Ahmed K, Harrison AD, Kunnimalaiyaan M, Chen H. Resveratrol induces
differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and
suppresses cell growth. Mol Cancer Ther. 2013 Jul;12(7):1276-87. PMCID: PMC3707971
71. Somnay Y, Chen H, Kunnimalaiyaan M. Synergistic effect of pasireotide and teriflunomide in carcinoids in
vitro. Neuroendocrinology. 2013;97(2):183-92. PMCID: PMC3546174
72. Burke JF, Schlosser L, Harrison AD, Kunnimalaiyaan M, Chen H. MK-2206 causes growth suppression and
reduces neuroendocrine tumor marker production in medullary thyroid cancer through Akt inhibition. Ann Surg
Oncol. 2013 Nov;20(12):3862-8. PMCID: PMC3955957
73. Dilip A, Cheng G, Joseph J, Kunnimalaiyaan S, Kalyanaraman B, Kunnimalaiyaan M, Gamblin TC.
Mitochondria-targeted antioxidant and glycolysis inhibition: synergistic therapy in hepatocellular carcinoma.
Anticancer Drugs. 2013 Oct;24(9):881-8. PMCID: PMC4028966
74. Wilson JM, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M. MK2206 inhibits hepatocellular carcinoma
cellular proliferation via induction of apoptosis and cell cycle arrest. J Surg Res. 2014 Oct;191(2):280-5.
75. Carter YM, Kunnimalaiyaan S, Chen H, Gamblin TC, Kunnimalaiyaan M. Specific glycogen synthase kinase-3
inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther. 2014
May;15(5):510-5. PMCID: PMC4026073
76. Wilson JM, Kunnimalaiyaan S, Kunnimalaiyaan M, Gamblin TC. Inhibition of the AKT pathway in
cholangiocarcinoma by MK2206 reduces cellular viability via induction of apoptosis. Cancer Cell Int.
2015;15(1):13. PMCID: PMC4324843
77. Kunnimalaiyaan S, Trevino J, Tsai S, Gamblin TC, Kunnimalaiyaan M. Xanthohumol-Mediated Suppression
of Notch1 Signaling Is Associated with Antitumor Activity in Human Pancreatic Cancer Cells. Mol Cancer Ther.
2015 Jun;14(6):1395-403. PMCID: PMC4554525
78. Koprowski S, Sokolowski K, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M. Curcumin-mediated
regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma. J Surg
Res. 2015 Oct;198(2):434-40.
79. Kunnimalaiyaan S, Sokolowski KM, Balamurugan M, Gamblin TC, Kunnimalaiyaan M. Xanthohumol inhibits
Notch signaling and induces apoptosis in hepatocellular carcinoma. PLoS One. 2015;10(5):e0127464. PMCID:
PMC4444108
80. Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M. Glycogen synthase kinase-3 inhibitor AR-A014418
suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression. HPB (Oxford).
2015 Sep;17(9):770-6. PMCID: PMC4557650
81. Kunnimalaiyaan S, Sokolowski KM, Gamblin TC, Kunnimalaiyaan M. Suberoylanilide hydroxamic acid, a
histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines. Am J Surg.
2017 Apr;213(4):645-651. doi: 1016/j.amjsurg.2016.12.001. Epub 2016 Dec 11. PMID: 28007318
Books, Chapters, and Reviews
1. Chen H, Kunnimalaiyaan M, Van Gompel JJ. Medullary thyroid cancer: the functions of raf-1 and human
achaete-scute homologue-1. Thyroid. 2005 Jun;15(6):511-21.
2. Kunnimalaiyaan M, Chen H. The Raf-1 pathway: a molecular target for treatment of select neuroendocrine
tumors? Anticancer Drugs. 2006 Feb;17(2):139-42.
3. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist.
2007 May;12(5):535-42.
4. Kunnimalaiyaan M, Haymart MR, Chen H. Tumor suppressor role of notch1 and raf-1 signaling in medullary
thyroid cancer cells. Transl Oncogenomics. 2007;2:43-7. PMCID: PMC3634621
5. Kevin M. Sokolowski, Mariappan Balamurugan, Selvi Kunnimalaiyaan, T. Clark Gamblin, Muthusamy
Kunnimalaiyaan. Notch signaling in hepatocellular carcinoma: molecular targeting in an advanced disease.
Hepatoma Research. 2015 1:11-15
6. Sokolowski KM, Koprowski S, Kunnimalaiyaan S, Balamurugan M, Gamblin TC, Kunnimalaiyaan M. Potential
Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer. Anticancer Agents Med Chem.
2016;16(1):29-37.
7. Sokolowski KM, Balamurugan M, Kunnimalaiyaan S, Wilson J, Gamblin TC, Kunnimalaiyaan M. Role of Akt
inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy. Am J Surg.
2016 Apr;211(4):755-60.
8. Somnay YR, Kunnimalaiyaan M. The Phosphatidylinositol 3-kinase/Akt Signaling Pathway in Neuroendocrine
Tumors. Glob J Biochem. 2012;3. PMCID: PMC5157925
9. Kunnimalaiyaan S, Sokolowski K, Gamblin TC, Kunnimalaiyaan M. Suberoylanilide hydroxamic Acid, a
histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines. Am J Surg.
2017 Apr;213(4):645-651.
Related documents